favor
bottom line publish outlook
us
pharmaceut coverag univers detail view pleas see
full deck
conjunct outlook piec upgrad glpg
share outperform neutral rais glpg target price
also downgrad share under-perform
outperform lower target price
detail view two stock pleas see companion
note publish earlier morn glpg
made estim chang
teva driven updat market model chang
estim led increas target price
decreas
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price month
humira sustain main concern
also cautiou pipelin asset
bottom line though expect earn dividend growth continu
help provid support stock near term remain
under-perform concern long-term outlook
compani concern sustain compani
flagship product humira given entri multipl humira biosimilar
eu well sign increas pressur us humira sale new
compet biolog beyond humira believ consensu estim
key pipelin product upadacitinib risankizumab high see
risk forecast
valuat maintain target price well under-perform
rate target price base dcf valuat wacc
termin growth rate revis ep estim
risk risk target price under-perform rate includ
better-than-expect sustain humira face biosimilar
especi key oncolog immunolog asset
 close
valuat metric
number share
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
 close
rapastinel data catalyst
bottom line construct compani core aesthet
busi continu remain area strength led botox
juvederm believ concern botox competit aesthet
migrain larg alreadi reflect stock howev believ
pipelin remain underappreci littl valu
current reflect stock price misstep rais question around
manag credibl led investor activ solid
execut good data upcom pipelin readout rapastinel
adjunct treatment depress could help mitig investor
valuat maintain outperform rate lower target price
driven larg lower sale oral cgrp target
price base blend dcf valuat rel
valuat assum wacc termin growth rate
dcf valuat use price-to-earnings multipl ep estim
rel valuat revis ep estim
risk risk target price outperform rate includ
greater-than-expect brand gener threat key product
botox vraylar linzess unexpect pipelin setback especi
oral cgrp abicipar rapastinel potenti disrupt commerci
execut addit manag chang
valuat metric
number share
price month
 close
allergan global brand pharmaceut compani develop
commerci product focus seven key therapeut
urolog anti-infect
blue sky valuat base greater sale botox
viberzi oral cgrp compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale key
market product botox restasi gi
franchis oral cgrp compar current base case
assumpt also model lower gross margin oper
margin base case assumpt grey sky valuat
base dcf driven wacc termin valu
price dec rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
depress expect wait
catalyst drive turnaround
bottom line maintain neutral rate believ
immuno-oncolog market potenti still underappreci
other still scope upsid especi earlier stage diseas
think still much sort opdivo yervoy combin
lung cancer beyond perhap begin becom
construct name though eliqui orencia continu grow
compani outlook remain highli tie success failur i-o success
data releas could lead turnaround main data
late
valuat maintain target price base
blend dcf valuat rel valuat assum
wacc termin growth rate dcf valuat use
multipl ep estim rel valuat revis
ep estim
risk risk target price neutral rate includ
disappoint increas excit around i-o/i-o data unexpect
 unexpect disruption/success earlier stage asset
valuat metric
number share
price month
 close
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
strong diversifi product stori valuat
signific premium group
bottom line see multipl posit compani valuat
signific premium group lead us believ posit
like alreadi price stock posit data cardiovascular
risk studi rewind along robust phase data dual
receptor agonist see continu growth longev
franchis help support diabet busi well
opportun upsid non-diabet busi well-respect
manag team along focu margin expans add
valuat maintain target price neutral rate
target price base sotp valuat lilli pharma
busi base dcf-deriv valuat
share busi assum wacc
termin growth rate dcf valuat pharma busi
ep unchang revis ep
risk risk target price neutral rate includ better-
worse-than-expect commerci ozemp captur market share
trulic success failur novo oral semaglutid better-or
worse-than-expect commerci newer product verzenio
taltz olumi emgal
valuat metric
number share
price month
 close
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
trulic jardianc taltz galcanezumab olumi verzenio
lartruvo compar current base case assumpt also
model higher gross margin oper margin base
case assumpt blue sky valuat base dcf driven
wacc termin valu assign lilli
share elanco per share
grey sky valuat base lower sale trulic
jardianc taltz galcanezumab olumi verzenio lartruvo
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
assign lilli share elanco per share
 close
bottom line outperform rate compani driven key
pharma growth driver xarelto darzalex imbruvica
schizophrenia franchis think continu deliv upsid
number financi strength provid upsid option
defens natur stori may attract appear
uncertain macro environ medic devic consum segment
continu under-perform pharma organ recoveri appear way
potenti set stage aggress busi develop
valuat rais target price maintain
outperform rate target price base blend dcf valuat
rel valuat assum wacc
termin growth rate dcf valuat use price-to-earnings multipl
ep estim rel valuat revis
ep estim
risk risk target price outperform rate includ
success competitor
key pharma product brand
biosimilar clinic failur pipelin product macro factor
reform us drug price
valuat metric
number share
price month
 close
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
price dec rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
less appreci driver upsid
bottom line outperform rate compani driven
potenti overal i-o/oncolog strategi believ remain
underappreci expect continu strong perform keytruda
driven increas adopt nsclc also think gardasil
remain underappreci see potenti upsid ou busi
potenti challeng rest busi januvia
encount gener competit believ issu
valuat rais target price maintain
outperform rate driven larg higher forecast keytruda
target price base blend dcf valuat rel
valuat assum wacc termin growth rate
dcf valuat price-to-earnings multipl ep estim
rel valuat ep remain unchang
revis ep
risk risk target price outperform rate includ
competit pressur key market product notabl
januvia/janumet better-than-expect pipelin data key
valuat metric
number share
price month
 close
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
price dec rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
price month
improv product stori lyrica
ibranc present challeng
bottom line see limit top line bottom line growth
given patent expir product viagra lyrica
competit challeng key product ibranc xtandi xalkori
outlook appear promis upsid driver
pipelin seem littl way
valuat rais target price maintain neutral
rate target price base blend dcf valuat
rel valuat assum wacc termin growth
rate dcf valuat use price-to-earnings multipl ep
estim rel valuat keep ep
chang ep estim
risk risk target price neutral rate includ better-
/worse-than-expect pipelin setback success specif
ibranc adjuv set vaccin oncolog asset
better-/worse-than-expect commerci busi develop
 close
valuat metric
number share
pfizer inc biopharmaceut compani engag
discoveri develop manufactur sale medicin
peopl anim world-wide
price dec rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
ibranc prevnar xtandi bavencio compar current base
case assumpt also model higher oper margin
base case assumpt blue sky valuat base dcf
driven wacc termin valu
grey sky valuat base lower sale ibranc
prevnar xtandi bavencio compar current base case
assumpt also model lower oper margin
base case assumpt grey sky valuat base dcf
driven wacc termin valu
 close
price month
ajovi austedo uptak critic overcom
gener pressur bring top-line growth
bottom line restructur effort progress nice
continu see modest top-line growth decad think
investor need see greater visibl growth get construct
expect brand product austedo ajovi nice growth
believ growth product larg off-set flattish growth
us gener busi continu declin copaxon lack
meaning near mid-term catalyst also keep us neutral name
valuat maintain target price neutral rate
target price deriv ev/ebitda ebitda estim
ep unchang ep increas
driven larg assumpt faster
ramp ajovi
risk risk target price neutral rate includ faster
anticip sale growth ajovi and/or austedo optim gener
combat price pressur better-/worse-than-expect
restructur compani
 close
valuat metric
number share
teva israel-bas pharmaceut compani focus primarili
research develop commerci gener
specialti drug two oper segment gener medicin
specialti medicin
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat driven larg part effici
optim gener busi slower anticip
eros copaxon sale launch new product
compani debt situat resolv effici
grey sky valuat driven larg part bearish
assumpt around sale copaxon gener
busi us need renogoti debt
 close
price month
bottom line maintain outperform rate full data
phase palisad show compel clinic profil posit
well head bla file expect fda grant applic
prioriti review statu set stage possibl approv commerci
launch due dilig suggest signific excit
allergi commun incorpor practic question
remain around approv main competitor viaskin patch even
get approv think market larg enough win
valuat target price calcul use probabl
adjust discount cash flow model base lead product
estim sale go use wacc termin valu
risk risk target price outperform rate includ failur
get approv better-than-expect approval/label dbvt
could impact potenti disappoint commerci
 close
valuat metric
number share
aimmun clinical-stag biopharma compani develop
desensit treatment protect peopl food allergi
life-threaten consequ accident exposur use
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po
popul us europ assum
captur market share blue sky valuat base
dcf driven wacc termin valu thereaft
grey sky valuat base po
popul patient po popul
patient us assum peak
penetr captur market share europ
assum peak penetr captur
market share grey sky valuat base dcf driven
wacc termin valu thereaft
 close
price month
eptinezumab profil better appreci
commerci could challeng
bottom line maintain neutral rate aldr face
challeng commerci setup three larger player ahead compani
multi-billion dollar migrain prophylaxi market intraven
formul provid opportun differenti think investor
unlik give credit execut demonstr increment pipelin
platform updat could drive upsid earli assign
valuat target price aldr calcul use probabl
adjust discount cash flow model base lead product eptinezumab
project cash flow use wacc
risk risk target price neutral rate includ earlier-
/later-than timelin reach profit estim reach
profit eptinezumab unanticip development setback
greater-than-expect competit pressur failur obtain approv
eptinezumab earlier-than-expect approv better-/worse-than
 close
valuat metric
number share
aldr develop novel antibodi treatment rang
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po
eptinezumab frequent episod migrain fem po
chronic migrain cm also assum aldr captur
market share fem market share cm
blue sky valuat base dcf driven wacc
forecast discount cash flow termin
grey sky valuat base po eptinezumab
frequent episod migrain fem po chronic
migrain cm also assum aldr captur
market share fem cm grey sky valuat base
dcf driven wacc forecast discount cash flow
termin growth rate thereaft
 close
limit catalyst turn around stori
bottom line downgrad rate under-perform follow seri
disappoint underwhelm pipelin catalyst see limit
driver upsid move remov forecast
depress lower sale forecast
schizophrenia given unexcit weight gain efficaci data also believ
consensu estim vivitrol aristada like high
need revis addit see lack meaning news flow
lift stock expect complet respons letter
given neg fda adcomm head-to-head data
vs tecfidera expect impact limit
partner like earli meaning
impact stock
valuat target price base
rel valuat dcf wacc termin growth
estim
risk risk target price under-perform rate includ
better-than-expect pipelin develop faster expect base
busi growth commerci later-than-
expect gener competit market product
valuat metric
number share
price month
 close
plc global biopharmaceut compani research
develop commerci partner
pharmaceut product design address central
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base vivitrol
schizophrenia franchis gener peak combin sale sale
blue sky valuat base dcf driven
wacc along termin growth rate thereaft
grey sky valuat base vivitrol gener
peak sale sale grey sky
valuat base dcf driven wacc along
 close
price month
expect regulatori clariti soon
initi phase data
bottom line maintain outperform rate lead asset reloxalias
shown encourag clinic profil solid efficaci
good safeti phase program enter hyperoxaluria market
limit competit reloxalias track first-in-class product
pipelin opportun exist reloxalias indic
asset leverag alna oral enzym technolog compani expect
interim data top-line data trial
valuat target price alna base dcf valuat
wacc perpetu growth rate
risk risk target price outperform rate includ
regulatori setback reloxalias phase program phase clinic
failur poor commerci execut reloxalias
 close
valuat metric
number share
allena clinical-stag pharmaceut compani
focus develop commerci oral enzym
therapi treat patient rare sever metabol disord
affect kidney
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base probabl
success fda approv lead asset higher
penetr sever moder enter
patient popul greater complianc rate blue sky
valuat base dcf driven wacc termin
grey sky valuat base probabl
success fda approv lead asset lower
penetr sever moder enter patient
popul lower complianc rate grey sky valuat
base dcf driven wacc termin valu
 close
price month
posit phase data wholli own
bottom line maintain outperform rate strong clinic profil
potenti approv could help fomx captur signific
share billion acn market also demonstr posit
efficaci treat papulopustular rosacea addit experienc
manag team histori success dermatolog plu
valuat target price fomx base dcf valuat
project cash flow use wacc termin
risk risk target price outperform rate includ
delay/deni approv poor commerci execut
 close
valuat metric
number share
foamix specialti pharmaceut compani focus
develop commerci foam-bas formul
treatment acn rosacea impetigo skin condit
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po fmx
po fmx also assum peak acn
market share peak rosacea market share blue sky
valuat base dcf driven wacc
discount cash flow termin growth rate
grey sky valuat base po fmx
po fmx grey sky valuat base dcf
driven wacc discount cash flow
termin growth rate thereaft
 close
price month
filgotinib focu multipl way win
bottom line upgrad glpg outperform rate see multipl
possibl pathway upsid broad filgotinib develop program
present larg opportun peak sale potenti given proof-of-
concept data indic addit indic phase
develop multipl addit pipelin asset also signific revenu
potenti success includ ipf osteoarthr atop
dermat strong cash posit scarciti valu provid upsid potenti
addit filgotinib phase data rheumatoid arthriti finch
finch next main catalyst stock
valuat dcf-deriv target price base dcf
valuat project cash flow use wacc
termin growth rate ep unchang revis
ep estim
risk risk target price outperform rate includ
development setback filgotinib clinic risk commerci risk
around pipelin asset
amsterdam exchang
close
valuat metric
number share
galapago clinic stage biotech compani focus
develop novel treatment rheumatoid arthriti inflammatori
bowel diseas idiopath pulmonari fibrosi atop dermat
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po filgotinib
better-than-expect data pipelin drug
blue sky valuat base
dcf driven wacc discount cash flow
termin growth rate thereaft
grey sky valuat base po filgotinib
worse-than-expect data pipelin drug
grey sky valuat base
dcf driven wacc discount cash flow
termin growth rate thereaft
amsterdam exchang close
price month
await detail upcom split
pipelin catalyst take time
bottom line maintain neutral think pipelin take time
play see signific catalyst would drive signific
upsid downsid stock think expect low-to-mid singl
digit sale growth lead asset linzess like reflect stock
upcom split compani may posit lack suffici
valuat target price base dcf valuat cash flow
forecast use termin growth rate
risk risk target price neutral rate includ greater-
than-anticip competit linzess amitiza trulanc
earlier-/later-than-expect execut pipelin better-/worse-than-
expect valu creation compani split
 close
valuat metric
number share
ironwood specialti pharmaceut compani involv
develop commerci drug gastrointestin condit
develop intern extern access
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base higher linzess
peak sale base case along higher probabl
success sale forecast pipelin asset
blue sky valuat base dcf driven
wacc along termin growth rate
grey sky valuat base lower
linzess peak sale base case sale pipelin
asset grey sky valuat base
dcf driven wacc along termin growth rate
 close
price month
andexxa approv critic allow
greater commerci uptak
bottom line think potenti andexxa signific think
investor wait-and-se mode success execut given
compani repeat misstep encouragingli new ceo
appoint relev commerci experi could help better
execut bevyxxa expect product
temper longer key part stori
valuat target price base dcf valuat cash
flow forecast use termin growth rate
risk risk target price neutral rate includ better-
/worse-than expect commerci andexxa bevyxxa
quicker-/slower-than-expect progress cerdulatinib
 close
valuat metric
number share
portola biopharmaceut compani focus
develop commerci novel therapeut
area thrombosi hematolog disord inflamm
patient current limit approv treatment
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base dcf analysi driven
combin global sale bevyxxa andexxa exceed
peak
 close
grey sky valuat base dcf analysi driven
combin sale bevyxxa andexxa peak
product sold ex-amort
tax earn
average share outstand
dilut ep oper
sale
research develop
sell gener administr
incom incom tax non-controlling
net incom continu oper
provis incom tax
incom discontinu oper net tax
incom loss attribut non-controlling interest
net incom attribut sharehold
weight average share calcul dilut ep
 includ mileston sale
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
sale
total incom expens
provis incom tax
good sold
total expens incom
incom tax basi
ep continu op
dilut ep oper
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
revenu
total incom expens
provis incom tax
sale
incom invest
incom incom tax
share loss associ compani net
net incom non-control interest
net gain loss attribut non-control interest
dividend prefer share
weight average share use calcul dilut ep
profit loss tax
weight average share calcul dilut ep
depreci amort
good
research develop
deem dividend convert prefer stock
dividend convert prefer stock
net income/ loss common stockhold
dilut ep oper
research develop revenu
amort acquir intang asset
chang fair valu conting consider
average number common share out non-gaap
 sale
sg sale
profit loss tax
weight average share use calcul dilut ep
interest incom net
profit loss tax
weight average share use calcul dilut ep
depreci amort
sale
net profit/ loss continu oper
weight average share calcul dilut ep
gross margin ex-royalti incom
write-dow inventori net realiz valu loss non-cancel purchas commit
research develop
sell gener administr
amort acquir intang asset
loss fair valu remeasur cont consider
profit/ loss deriv
total expens net
profit loss tax
weight average share calcul dilut ep
collabor licens revenu
good sold
incom loss oper
interest incom net
incom loss incom tax
provis incom tax
net incom attribut non-controlling interest
net incom loss attribut portola
charl martineau univers toronto compani mention price
